ÖZET
Osteoporoz, dünya çapında yaygın olarak görülen, kemik mineral dansitesinde azalma ve kırık riskinde artış ile karakterize sistemik metabolik bir hastalıktır. Önlenmesi ve tedavisinde bifosfonatlar yaygın olarak tercih edilmektedir. Oral ve parenteral olarak kullanılan bifosfonatların yan etkileri arasında gastrointestinal semptomlar, kas iskelet sistemi ağrıları, flu-like sendrom, akut faz reaktanlarında artış bulunmaktadır. Bu olgu sunumunda, alendronat tedavisi sırasında nadir gözlenen bir yan etki olarak poliartiküler sinovit olgusu sunulacaktır.
References
1
Abboskhujaeva LS, Ismailov SI, Alikhanova NM. Efficacy of strontium ranelate in combination with a D-hormone analog for the treatment of postmenopausal osteoporosis. Drugs R D 2014;14:315-24.
2
Sambrook P, Cooper C. Osteoporosis. Lancet 2006;367:2010-8.
3
Cauley JA, Thompson DE, Ensrud KC, Scott JC, Black D. Risk of mortality following clinical fractures. Osteoporos Int 2000;11:556-61.
4
Manolagas SC, O’Brien CA, Almeida M. The role of estrogen and androgen receptors in bone health and disease. Nat Rev Endocrinol 2013;9:699-712.
5
Davison KS, Siminoski K, Adachi JD, Hanley DA, Goltzman D, Hodsman AB, et al. The effects of antifracture therapies on the components of bone strength: assessment of fracture risk today and in the future. Semin Arthritis Rheum 2006;36:10-21.
6
MacLean C, Newberry S, Maglione M, McMahon M, Ranganath V, Suttorp M, et al. Systematic review: comparative effectiveness of treatments to prevent fractures in men and women with low bone density or osteoporosis. Ann Intern Med 2008;148:197-213.
7
Bisphosphonates for osteoporosis. Drug Ther Bull 2001;39:68-72.
8
US Food and Drug Administration. Bisphosphonates (marketed as Actonel, Actonel+Ca, Aredia, Boniva, Didronel, Fosamax, Fosamax+D, Reclast, Skelid, and Zometa). 2009. Available from:s URL: https://wayback.archive-it.org/7993/20161022053007/http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm101551.htm Accessed May 29, 2009.
9
Reid IR, Gamble GD, Mesenbrink P, Lakatos P, Black DM. Characterization of and risk factors for the acute-phase response after zoledronic acid. J Clin Endocrinol Metab 2010;95:4380-7.
10
Ruggiero SL. Bisphosphonate-related osteonecrosis of the jaw: an overview. Ann N Y Acad Sci 2011;1218:38-46.
11
Wang YK, Qin SQ, Ma T, Song W, Jiang RQ, Guo JB, et al. Effects of teriparatide versus alendronate for treatment of postmenopausal osteoporosis: A meta-analysis of randomized controlled trials. Medicine (Baltimore) 2017;96:e6970.
12
Cremers S, Drake MT, Ebetino FH, Bilezikian JP, Russell RGG. Pharmacology of bisphosphonates. Br J Clin Pharmacol 2019;85:1052-62.
13
Gwynne Jones DP, Savage RL, Highton J. Alendronate-induced synovitis. J Rheumatol 2008;35:537-8.
14
Reid IR. Bisphosphonates: new indications and methods of administration. Curr Opin Rheumatol 2003;15:458-63.
15
Kennel KA, Drake MT. Adverse effects of bisphosphonates: implications for osteoporosis management. Mayo Clin Proc 2009;84:632-7.
16
Khosla S, Bilezikian JP, Dempster DW, Lewiecki EM, Miller PD, Neer RM, et al. Benefits and risks of bisphosphonate therapy for osteoporosis. J Clin Endocrinol Metab 2012;97:2272-82.
17
Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley CA, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007;356:1809-22.
18
U.S. Food and Drug Administration. Early communication of an ongoing safety review: bisphosphonates: alendronate (Fosamax, Fosamax plus D), etidronate (Didronel), ibandronate (Boniva), pamidronate (Aredia), risedronate (Actonel, Actonel w/calcium), tiludronate (Skelid), and Zoledronic acid (reclast, zometa). Available from: s URL: https://wayback.archive-it.org/7993/20161022204214/http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm070303.htm Updated 2008. Accessed March 11, 2015.
19
Kim SY, Kim MJ, Cadarette SM, Solomon DH. Bisphosphonates and risk of atrial fibrillation: a meta-analysis. Arthritis Res Ther 2010;12:R30.
20
Pazianas M, Cooper C, Ebetino FH, Russell RG. Long-term treatment with bisphosphonates and their safety in postmenopausal osteoporosis. Ther Clin Risk Manag 2010;6:325-43.
21
The Uppsala Monitoring Centre. Alendronic Acid and Synovitis. Signal, March 2003. (Restricted Document). Contact the Uppsala Monitoring Centre for Details. e-mail: [email protected].
22
Frederiksen L, Junker P, Brixen KT. Persisterende polyartikulaer synovitis efter behandling med alendronat [Persistent polyarticular synovitis after treatment with alendronate]. Ugeskr Laeger 2007;169:1583-4.
23
Gökkus K, Yazicioglu G, Sagtas E, Uyan A, Aydin AT. Possible alendronate-induced polyarticular synovitis. J Postgrad Med 2016;62:126-8.
